RecruitingPhase 3NCT07686263

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Enrollment

472 participants

Start Date

Aug 20, 2026

Study Type

INTERVENTIONAL

Conditions

Schizophrenia

Summary

The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called Xanomeline/Trospium Chloride for people with schizophrenia. The study is currently recruiting participants at 59 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGXanomeline/Trospium Chloride

Specified dose on specified days

DRUGPlacebo

Specified dose on specified days

Locations(59)

Pillar Clinical Research - Bentonville

Bentonville, Arkansas, United States

Pillar Clinical Research- Little Rock

Little Rock, Arkansas, United States

Local Institution - 0021

Little Rock, Arkansas, United States

Local Institution - 0153

Rogers, Arkansas, United States

Local Institution - 0190

Anaheim, California, United States

Local Institution - 0040

Bellflower, California, United States

Local Institution - 0188

Chino, California, United States

Local Institution - 0032

Culver City, California, United States

Local Institution - 0037

Garden Grove, California, United States

Local Institution - 0068

La Habra, California, United States

Local Institution - 0128

Lemon Grove, California, United States

Local Institution - 0187

Montclair, California, United States

Local Institution - 0151

Orange, California, United States

Local Institution - 0030

Pico Rivera, California, United States

Local Institution - 0185

Redlands, California, United States

Local Institution - 0186

Riverside, California, United States

Local Institution - 0193

Torrance, California, United States

Research Centers of America ( Hollywood )

Hollywood, Florida, United States

Local Institution - 0075

Miami, Florida, United States

Local Institution - 0054

Miami Lakes, Florida, United States

Local Institution - 0134

Miami Springs, Florida, United States

Local Institution - 0195

Oakland Park, Florida, United States

Local Institution - 0044

West Palm Beach, Florida, United States

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Local Institution - 0070

Sandy Springs, Georgia, United States

Local Institution - 0189

Savannah, Georgia, United States

Local Institution - 0067

Chicago, Illinois, United States

Local Institution - 0056

Chicago, Illinois, United States

Local Institution - 0192

Gaithersburg, Maryland, United States

Local Institution - 0183

Cincinnati, Ohio, United States

Local Institution - 0047

Oklahoma City, Oklahoma, United States

Local Institution - 0049

Austin, Texas, United States

Local Institution - 0194

Dallas, Texas, United States

Pillar Clinical Research - Richardson

Richardson, Texas, United States

Local Institution - 0175

Río Cuarto, Córdoba Province, Argentina

Local Institution - 0143

Buenos Aires, Argentina

Local Institution - 0002

Córdoba, Argentina

Local Institution - 0144

Santiago del Estero, Argentina

Local Institution - 0191

Novi Iskar, Bulgaria

Local Institution - 0162

Brno, Czechia

Local Institution - 0014

Klecany, Czechia

Local Institution - 0159

Aarhus, Central Jutland, Denmark

Local Institution - 0182

Hovedvejen 19, Frederiksberg, Denmark

Local Institution - 0157

Glostrup, Region Sjælland, Denmark

Local Institution - 0158

Aalborg, Denmark

Local Institution - 0123

Warsaw, Masovian Voivodeship, Poland

Local Institution - 0122

Bialystok, Podlaskie Voivodeship, Poland

Local Institution - 0001

Poznan, Poland

Local Institution - 0103

Bucharest, Bucharest, Romania

Local Institution - 0105

Bucharest, Bucharest, Romania

Local Institution - 0107

Bucharest, Bucharest, Romania

Local Institution - 0110

Bucharest, Bucharest, Romania

Local Institution - 0174

Bucharest, Romania

Local Institution - 0106

Bucharest, Romania

Local Institution - 0109

Bucharest, Romania

Local Institution - 0112

Barcelona, Barcelona [Barcelona], Spain

Local Institution - 0167

Valladolid, Spain

Local Institution - 0181

Zamora, Spain

Local Institution - 0094

Cambridge, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07686263

Related Trials

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT071459187 locations

Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia

NCT03911726

A Study of Brenipatide in Adult Participants With Schizophrenia

NCT07410507102 locations

52-week Open Label Safety-Tolerability Study

NCT0736915423 locations

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

NCT0728856739 locations